Yubal, Dasch H.

HRN: 18-91-99  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/22/2023
10/29/2023
IV
80mg
TID
Dengue Fever With WS
Checking Final Appropriateness 

Indication:  ProphylaxisEmpiric    Type of Infection:  BloodstreamProphylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: